Blue Wave: Equity Turned Positive on Paper, but Cash Is Still Almost Gone

Company Introduction

Blue Wave is no longer a cannabis company, but it is still not an operating water company either. By the end of 2025 this was a tiny listed platform with a market cap of about NIS 9.5 million, a stock on the preservation list, a headquarters staff of 4 employees and service providers, a 17.81% stake in Copter, and distribution rights in products that still have not proven commercialization. That is the right way to read this report. Anyone looking only at the name change, the move into cleantech, and the return to positive equity may miss that the active bottleneck is still cash.

What is working now? The second milestone in Copter was completed on August 31, 2025, cumulative investment reached NIS 1.85 million, and Blue Wave gained deeper governance access through veto rights, a board seat, and broader commercial rights. In the Petah Tikva mikvah pilot, the system operated through January 14, 2026, and during the trial the water was found clear and bacteria-free except for technical issues that were identified and fixed. The hydroponic trial also showed statistically significant crop-weight improvement in some cycles, with no observed plant toxicity.

What is still not clean? At year end, cash was down to only NIS 19 thousand, working capital was negative by NIS 1.338 million, and the auditor drew attention to significant doubt about the company's ability to continue as a going concern. This is not a footnote. Even after NIS 2.081 million of financing cash inflow during the year, Blue Wave ended 2025 with almost no cash left.

There is another easy misread here. Equity turned positive at NIS 338 thousand, but in practice that rests on a NIS 1.676 million carrying value for the Copter investment. Blue Wave's share of Copter's net assets was already negative by NIS 106 thousand, and the rest of the carrying amount is made up of NIS 1.377 million of goodwill and NIS 405 thousand of intangible assets. In other words, the balance-sheet improvement is primarily accounting. It does not mean the funding problem has been solved.

And the story does not stop at water. In December 2025 the company set up Twenty Four Six Technologies, a subsidiary for automated FX trading software. After the balance-sheet date it signed a letter of intent with a Swiss entity for an AMC product, and in January 2026 it terminated the Bright Way negotiation, among other reasons because of its intention to enter the currency-trading field. That adds optionality. It also spreads management attention, time, and capital.

The Economic Map

This chart is the key to the opening read. At first glance you see the shift from negative to positive equity. One layer deeper, you see that the gap between current assets and current liabilities barely improved. So 2025 did not end the liquidity squeeze. It only replaced part of it with an investment carrying value.

Events And Triggers

The first trigger: Copter moved forward, but it did not cross into commercialization. The second milestone was completed on August 31, 2025 after cumulative milestone-two payments of NIS 790 thousand during April through August, and by year end Blue Wave held 17.81% of Copter's issued and paid-up capital, or 15.12% on a diluted basis. After completion of that milestone, Blue Wave enjoys director rights, veto rights, and distribution rights that remain in force even without continued investment after milestone two. That is important progress. It is still not cash.

The second trigger: the commercial rights look stronger than the commercial execution. Under the amended agreement, Blue Wave has worldwide exclusivity in water purifiers for mikvahs, exclusivity in hydroponics in Israel, Asia, and Africa, and additional rights in swimming-pool water purification. On the other hand, those rights remain subject to annual sales milestones, and the business chapter still states that as of the report date the company and Copter had no customers, no order backlog, and no active sales and distribution setup.

The third trigger: the pilots produced partial proof of concept, not product proof. In the Kfar Chabad mikvah pilot, usage loads reached up to about 600 bathers a day, versus about 150 bathers a day in the Petah Tikva mikvah, and the company concluded that a stronger system would be needed for heavily used mikvahs. In the Petah Tikva pilot, the system showed improved anti-bacterial activity, but the company still estimates that about NIS 150 thousand of additional funding is needed to advance an improved prototype with filtration, a stainless-steel propeller, and a quieter, more reliable motor. In hydroponics, the results were mixed: some growth cycles showed higher crop weight, but the system also suffered clogs and operational failures, and the report explicitly says there is no planned continuation of the trial in its current form.

The fourth trigger: management kept opening new strategic options before the first one had been proven. In December 2025, Twenty Four Six Technologies was established. In February 2026, it signed a letter of intent with Swiss regulated asset manager AMS for possible technological cooperation around an AMC product. At the same time, on January 18, 2026, Blue Wave announced the termination of the Bright Way negotiation, among other reasons because of its intention to enter the currency-trading field. Read together, this sequence says the company is still searching for a final operating shape.

This chart matters because it shows the price of the option. NIS 1.85 million had bought only 15.12% diluted ownership by year end. The road to 40% is still long and expensive, and every future milestone requires more money before there is a stable commercial business.

Efficiency, Profitability, And Competition

The core insight is that Blue Wave still does not own an operating business with real operating economics. At the parent-company level there is no revenue at all. At Copter level there was already revenue of NIS 224 thousand in 2025, but against that sat NIS 1.539 million of expenses and a NIS 1.315 million loss. That does not mean there is no progress. It does mean the progress is still very expensive relative to the revenue base.

The more interesting gap is between the numbers and the wording of the business section. Note 5 shows revenue at Copter. Yet in the business chapter, as of the report date, the company still says there are no customers, no backlog, no active marketing and distribution setup, and no expectation of sales in the near term. This is not only a drafting inconsistency. It signals that management itself is not presenting 2025 as a commercialization year. It is presenting it as a development year with early revenue, not as the start of a real sales engine.

That is the heart of the argument. It is possible to get excited by the move from almost zero revenue to NIS 224 thousand. It is not yet possible to call this product economics. Every shekel of revenue still arrives against an expense base that is many times larger.

The Commercialization Ladder Is Still Short

The operating structure itself shows how early the story still is. As of the report date, Blue Wave had 4 employees and service providers. Copter itself had no employees as of the report date, and its human-capital table shows only 2 employees and service providers as of December 31, 2025. In addition, Copter is still producing individual units with external suppliers, and the existing assembly line is designed for current pilot needs. This is not yet an operating layer that can absorb a real demand step-up without additional capital and a much cleaner outsourcing setup.

The Technology Moat Exists, But It Is Not As Clean As The Headline Suggests

Copter has several active patent filings, and in February 2026 it even filed a new PCT application in agricultural irrigation that is owned by Copter. That is the positive side. On the other hand, one of the key patents already granted in the US is not owned directly by Copter. It is owned by the founders and the Sami Shamoon Academic College, while Copter holds a license to use it for water disinfection. So there is an IP layer here, but not all of the moat sits in direct and simple ownership.

Competition Has Not Yet Been Tested In The Market, Mostly In Pilots

The company says that to the best of its knowledge there is no water purifier in the market based on monovalent copper ions. That is a real differentiator. But it is not worth much yet without regulatory clearance, without customers, and without backlog. In both mikvah and hydroponics, the comparison is still mainly against existing methods such as chlorine, ozone, or UV, not against a market that has already chosen Copter as its preferred commercial product.

Cash Flow, Capital Structure, And Balance Sheet

This is not a debt story. It is a dilution story. There is no heavy bank-maturity wall or stressed covenant package here. There is a different story: a company that survives from issuance to issuance in order to keep funding both Copter and the new software activity.

To avoid confusion, this is a case where the all-in cash flexibility view is the right framework. The question is not how much "normalized" cash the business might produce one day. The question is how much cash was actually left after all real uses during the year. On that view, 2025 looks very sharp: opening cash of NIS 398 thousand, operating cash outflow of NIS 1.67 million, investing outflow of NIS 790 thousand, financing inflow of NIS 2.081 million, and year-end cash of only NIS 19 thousand.

That chart explains why the better-looking balance sheet is not enough. Even after a relatively active year in the capital market, almost no cash remained.

Equity Issuance Was Booked, But Not All Of It Reached The Cash Box In Time

The statement of changes in equity shows NIS 2.592 million of share issuance net of issuance expenses in 2025. The cash-flow statement, by contrast, shows only NIS 2.081 million of financing cash inflow. The gap is explained in Annex B to the cash-flow statement: NIS 452 thousand was still receivable from share issuance and was collected only after the balance-sheet date, while another NIS 75 thousand was booked as shares issued under a court judgment rather than cash. This looks like a small technical detail, but it matters. It means that even inside the capital raises themselves, not all of the "equity" was usable cash by December 31, 2025.

On the liability side there is no bank debt, but there is real short-term pressure. Out of NIS 1.894 million of payables and accruals, NIS 721 thousand are liabilities to current and former directors, and NIS 945 thousand are accrued expenses. So the issue is not a wall of external debt. The issue is that the company is carrying a short-term liability stack without a real cash cushion.

Positive Equity Is Built Mostly On Goodwill

This is one of the most important numbers in the report. The Copter investment is carried at NIS 1.676 million, but Blue Wave's share in Copter's net assets is already negative NIS 106 thousand. In other words, most of the carrying value does not sit on net assets. It sits on goodwill and an intangible asset created through purchase-price allocation.

That does not automatically mean the investment is worth less. It does mean that Blue Wave's positive equity is not backed by cash, not backed by current assets, and not backed by a positive share of Copter's net assets. It is backed by expectations about future commercialization.

The Immediate Funding Door Is Still Narrow

On March 31, 2026 the board approved a 6-month extension of the exercise period for 240,909 options that had been granted to investors in April 2025. That may sound like funding oxygen. In practice, even if every one of those options is exercised, and using the original exercise prices, the company would receive at most about NIS 439 thousand. That is not negligible for a company of this size, but it is still smaller than the working-capital deficit and far below Copter's future funding needs.

There is another yellow flag here. As of the report date, the company no longer had an effective shelf prospectus. Even before that, the Israel Securities Authority had been examining the question of whether the company should be viewed as a shell, and any shelf offering under the old shelf prospectus would have required a specific permit. The practical meaning is straightforward: even the next capital raise may not be frictionless.

Forward Look

Before getting into the details, these are the 4 non-obvious conclusions from the report:

• Equity turned positive, but not because of operating progress. It turned positive mainly because of Copter's carrying value.
• Copter milestone two did not close the story, it only bought the right to keep funding it. The remaining milestones could require another NIS 5.55 million, and there is also an optional NIS 1.295 million investment right.
• Copter's early revenue still does not create a commercial base. Otherwise the same report would not contain both recorded revenue in Note 5 and a statement that there are no customers, no backlog, and no sales expected in the near term.
• The option extension is a small bridge, not a solution. Full exercise of the extended options would still not close the liquidity gap.

2026 Looks Like A Financing Bridge Year

Right now 2026 looks like a financing bridge year, not a breakout year. First cash, then customers. Blue Wave still faces material Copter milestones: a third milestone of NIS 1.85 million with an additional NIS 1.295 million investment option, a fourth milestone of NIS 1.85 million, and a fifth milestone of NIS 1.85 million. In total that is up to NIS 6.845 million of potential future capital, a very large number relative to the current market cap.

The positive side is that after milestone two, Blue Wave's distribution rights remain in force regardless of whether it continues investing. That is created value. But it is still not accessible value for shareholders, because the products have not yet completed the commercialization path and the rights themselves are tied to annual sales thresholds.

What Has To Happen Over The Next 2 To 4 Quarters

First, the company needs a cleaner and closer funding solution. NIS 19 thousand of year-end cash, NIS 452 thousand collected after the balance-sheet date, and even NIS 439 thousand of potential option cash do not build a comfortable 12-month runway.

Second, Copter needs to move from development to measurable commercial progress. That means either completion of the PRD linked to milestone three, or the appearance of customers and backlog that allow the story to be read as commercialization rather than experimentation. Without one of those two things, the company remains stuck between pilots and the capital market.

Third, management needs to decide whether the automated-trading software activity is a real engine or just another option that was opened too early. The document with AMS is only a letter of intent. It is not revenue, and it does not bind the activity to completion.

What could change the market's short-term reading? A real financing announcement, actual option exercises, any sign that Copter has moved from pilots to customers, or, on the other side, another update that expands the strategy into new areas without closing the open issues in water. At this market cap, any one of those events can quickly change interpretation.

Risks

The first risk: funding. This is the clearest and heaviest risk. The company itself says it needs capital raises to fund the coming months. Management can try to optimize spending, but without new money it is hard to see how both Copter and 24/6 move forward in parallel.

The second risk: immature commercialization. The pilots produced encouraging signals, but they also exposed malfunctions, a need to improve the prototype, and in the hydroponic trial the report explicitly says there is no planned continuation. As long as there are no customers, no backlog, and no near-term sales expectation, the story remains very early.

The third risk: the gap between created value and accessible value. A NIS 1.676 million carrying value in an investment whose share of net assets is negative is not a cash cushion. If commercialization is delayed, shareholders are left with a balance sheet that looks better than the company's actual ability to fund itself.

The fourth risk: strategic dispersion. Moving from cannabis to water already requires focus. Opening a second field in algorithmic trading, alongside a negotiation that opened and then closed around Bright Way, raises the risk that Blue Wave keeps behaving like a listed platform searching for the next story rather than like a company building one commercial path.

The fifth risk: the IP and execution layer is less clean than the headline suggests. One of the key patents is licensed to Copter rather than directly owned by it, Copter has no employees as of the report date, and current production relies on external suppliers. That does not kill the thesis, but it shows that the moat is not yet backed by a mature operating structure.

---

Conclusions

Blue Wave finishes 2025 with a clearer thesis, but not with a cleaner company. Copter progressed, the investment grew, and the governance and distribution rights improved. On the other hand, the cash drawer is almost empty, working capital remains negative, and the value created so far sits mainly on hope for future commercialization rather than on cash or liquid assets.

In the short to medium term, the market will not judge Blue Wave on whether it has a story. It already has one. It will judge the company on three much simpler checkpoints: whether cash comes in, whether Copter turns into customers and backlog, and whether the automated-trading activity is a real plan or just another dilution of focus.

Current thesis: Blue Wave ended 2025 with positive equity on paper, but its actual economics still look like those of a tiny funding platform financing one option in water and a second option in software.

What changed: the company completed Copter's second milestone, changed sector classification, and added a new software activity. But it did not solve funding, and it did not build a proven commercial base.

Counter-thesis: at a market cap of only about NIS 9.5 million, the market may already be over-penalizing the financing risk. If Copter turns the pilots into customers and Blue Wave can exploit its distribution rights without being forced through the entire investment path, the option value could exceed what the balance sheet currently suggests.

What can change the market read: real financing, completion of the third milestone, visible customers and backlog at Copter, or, on the negative side, proof that the company keeps expanding into new ideas without closing the old one.

Why this matters: in micro-cap names like Blue Wave, the distinction between an accounting asset and accessible cash is the whole story. If readers confuse the two, they read the company backwards.

What has to happen next: the company first needs to secure funding, then show commercialization, and at the same time decide whether it is building one coherent story or continuing to hold several small options in parallel.